AU634655B2 - Pyridazinone derivative - Google Patents

Pyridazinone derivative Download PDF

Info

Publication number
AU634655B2
AU634655B2 AU76511/91A AU7651191A AU634655B2 AU 634655 B2 AU634655 B2 AU 634655B2 AU 76511/91 A AU76511/91 A AU 76511/91A AU 7651191 A AU7651191 A AU 7651191A AU 634655 B2 AU634655 B2 AU 634655B2
Authority
AU
Australia
Prior art keywords
group
straight chained
alkyl group
branched
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU76511/91A
Other languages
English (en)
Other versions
AU7651191A (en
Inventor
Takashi Matsumoto
Akira Saito
Ryozo Sakoda
Kenichi Shikada
Keizo Tanikawa
Nobutomo Tsuruzoe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissan Chemical Corp
Original Assignee
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Corp filed Critical Nissan Chemical Corp
Publication of AU7651191A publication Critical patent/AU7651191A/en
Application granted granted Critical
Publication of AU634655B2 publication Critical patent/AU634655B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
AU76511/91A 1990-04-25 1991-04-19 Pyridazinone derivative Expired AU634655B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP10991490 1990-04-25
JP2-109914 1990-04-25

Publications (2)

Publication Number Publication Date
AU7651191A AU7651191A (en) 1991-11-11
AU634655B2 true AU634655B2 (en) 1993-02-25

Family

ID=14522343

Family Applications (1)

Application Number Title Priority Date Filing Date
AU76511/91A Expired AU634655B2 (en) 1990-04-25 1991-04-19 Pyridazinone derivative

Country Status (17)

Country Link
US (3) US5202323A (enExample)
EP (1) EP0482208B1 (enExample)
JP (1) JPH07107055B2 (enExample)
KR (1) KR970002876B1 (enExample)
AT (1) ATE194835T1 (enExample)
AU (1) AU634655B2 (enExample)
CA (1) CA2053863C (enExample)
DE (1) DE69132329T2 (enExample)
DK (1) DK0482208T3 (enExample)
ES (1) ES2149761T3 (enExample)
GR (1) GR3034331T3 (enExample)
HU (1) HU208124B (enExample)
RU (1) RU2054004C1 (enExample)
TW (1) TW204348B (enExample)
UA (1) UA27031A1 (enExample)
WO (1) WO1991016314A1 (enExample)
ZA (1) ZA913134B (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0482208B1 (en) * 1990-04-25 2000-07-19 Nissan Chemical Industries Ltd. Pyridazinone derivative
US5403590A (en) * 1992-12-21 1995-04-04 New England Deaconess Hospital Corporation Method of pulsatile drug infusion
JP3080131B2 (ja) 1993-06-29 2000-08-21 日産化学工業株式会社 ピリダジノン誘導体
IL110040A (en) * 1993-06-29 2000-07-16 Nissan Chemical Ind Ltd Pyridazinone derivatives their preparation and pharmaceutical compositions comprising them
AU681694B2 (en) * 1993-09-06 1997-09-04 Ishihara Sangyo Kaisha Ltd. Pyridazinone derivatives or their salts, processes for theirproduction, and anti-shock agents containing them
NZ270130A (en) * 1993-12-16 1995-12-21 Nihon Nohyaku Co Ltd Pyridazinone derivatives, preparation and pharmaceutical compositions thereof
ATE192741T1 (de) * 1994-01-25 2000-05-15 Nissan Chemical Ind Ltd Pyridazinon-derivate
IL112695A (en) * 1994-02-22 1999-04-11 Green Cross Corp Pharmaceutical compositions containing pyridazinone derivatives
GB9514160D0 (en) * 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
US5670504A (en) * 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
TW434240B (en) 1995-06-20 2001-05-16 Zeneca Ltd Aromatic compounds, preparation thereof and pharmaceutical composition comprising same
ES2188957T3 (es) 1996-06-27 2003-07-01 Janssen Pharmaceutica Nv N-(4-(heteroarilmetil)fenil)-heteroarilaminas.
TW482675B (en) * 1997-01-31 2002-04-11 Green Cross Corp Compositions for oral administration containing pyridazinone compounds technical field of the invention
JP4352613B2 (ja) * 1997-08-28 2009-10-28 日産化学工業株式会社 血管新生促進剤及び血管新生作用増強剤
RU2211217C2 (ru) * 1998-06-05 2003-08-27 Эгиш Дьёдьсердьяр Рт. Способ получения 5-хлор-4-аминозамещенного производного 3(2н)-пиридазинона
AU5445699A (en) * 1998-09-01 2000-03-21 Nissan Chemical Industries Ltd. Remedies for spinal canal stenosis
NZ512754A (en) * 1998-12-07 2002-10-25 Nissan Chemical Ind Ltd Remedial agent for erectile dysfunction containing a 3(2H)-pyridazinone derivative
DE20009841U1 (de) * 2000-05-31 2001-10-25 Phyt-Immun GmbH, 66424 Homburg Nasensalbe auf Basis von Vaselin
CN1259316C (zh) * 2001-04-05 2006-06-14 托伦脱药品有限公司 用于老龄相关性和糖尿病性血管系统并发症的杂环类化合物
US7399864B2 (en) * 2001-05-02 2008-07-15 Otsuka Pharmaceutical Co., Ltd. Process for producing carbostyril derivatives
US20050101631A1 (en) * 2002-08-01 2005-05-12 Otsuka Pharmaceuticals Company Process for producing carbostyril derivatives
MXPA03010672A (es) 2001-05-23 2004-03-02 Tanabe Seiyaku Co Composicion para el tratamiento regenerativo de enfermedades del cartilago.
KR20040007596A (ko) 2001-05-23 2004-01-24 다나베 세이야꾸 가부시키가이샤 골절 치료 촉진용 조성물
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1913942B1 (en) * 2003-09-09 2009-11-11 Biogen Idec International GmbH The use of fumaric acid derivatives for inhibition of PGF-induced thymidine uptake of bronchial smooth muscle cells and for inhibition of bronchial smooth cells proliferation
RU2356555C2 (ru) * 2003-12-26 2009-05-27 Ниссан Кемикал Индастриз, ЛТД Антинейтрофильное средство
WO2005074938A1 (ja) * 2004-02-09 2005-08-18 Nissan Chemical Industries, Ltd. 血管内膜肥厚抑制薬
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
DK2170930T3 (da) 2007-06-04 2012-11-05 Synergy Pharmaceuticals Inc Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010074090A1 (ja) 2008-12-25 2010-07-01 日産化学工業株式会社 ピリダジン－３（２ｈ）－オン化合物塩酸塩の結晶及びその製造方法
SG177384A1 (en) 2009-06-29 2012-02-28 Incyte Corp Pyrimidinones as pi3k inhibitors
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
WO2011075630A1 (en) * 2009-12-18 2011-06-23 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
US8912192B2 (en) 2010-02-12 2014-12-16 Taisho Pharmaceutical Co., Ltd Extended release preparation
WO2011130342A1 (en) 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AR084366A1 (es) 2010-12-20 2013-05-08 Incyte Corp N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k
US9580471B2 (en) 2011-03-01 2017-02-28 Synergy Pharmaceuticals, Inc. Process of preparing guanylate cyclase C agonists
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
KR102249236B1 (ko) 2011-09-02 2021-05-10 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
WO2014131024A2 (en) 2013-02-25 2014-08-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
MX375926B (es) 2013-08-09 2025-03-07 Ardelyx Inc Compuestos y metodos para inhibir el transporte de fosfato.
AU2014318837B2 (en) 2013-09-12 2019-05-30 Janssen Biopharma, Inc. Pyridazinone compounds and uses thereof
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
MX388606B (es) 2015-02-27 2025-03-19 Incyte Holdings Corp Sales del inhibidor fosfoinositida 3-cinasa (pi3k) y procesos para su preparacion.
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
CN107793362B (zh) * 2016-08-30 2022-04-22 江苏恩华药业股份有限公司 一种苯基哒嗪酮类衍生物的合成及其应用
SG11202011680YA (en) 2018-06-01 2020-12-30 Incyte Corp Dosing regimen for the treatment of pi3k related disorders
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU597141B2 (en) * 1987-01-20 1990-05-24 Nissan Chemical Industries Ltd. 3(2h)pyridazinone, process for its preparation and antagonistic agent against srs-a containing it
EP0376079A1 (en) * 1988-12-20 1990-07-04 Nissan Chemical Industries Ltd. 3(2H)pyridazinones, processes for their preparation and antagonistic agent against SRS-A

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2534893A1 (de) * 1975-08-05 1977-02-17 Bayer Ag (thiono)(thiol)pyridazinonalkanphosphonsaeureester, verfahren zu ihrer herstellung sowie ihre verwendung als insektizide und akarizide
CA1265798A (en) * 1984-12-10 1990-02-13 Motoo Mutsukado 3(2h)pyridazinone, process for its preparation and anti-allergic agent containing it
ES2031821T3 (es) * 1985-10-17 1993-01-01 Smith Kline & French Laboratories Limited Procedimiento para preparar derivados de 4(4-oxo-1,4-dihidropiridin-1-il)fenilo.
JP2550631B2 (ja) * 1987-01-20 1996-11-06 日産化学工業株式会社 ピリダジノン誘導体
IE62890B1 (en) * 1988-12-06 1995-03-08 Hafslund Nycomed Pharma New piperazinylalkyl-3(2h)-pyridazinones process for the preparation thereof and the use thereof as agents lowering blood pressure
EP0482208B1 (en) * 1990-04-25 2000-07-19 Nissan Chemical Industries Ltd. Pyridazinone derivative

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU597141B2 (en) * 1987-01-20 1990-05-24 Nissan Chemical Industries Ltd. 3(2h)pyridazinone, process for its preparation and antagonistic agent against srs-a containing it
EP0376079A1 (en) * 1988-12-20 1990-07-04 Nissan Chemical Industries Ltd. 3(2H)pyridazinones, processes for their preparation and antagonistic agent against SRS-A

Also Published As

Publication number Publication date
DK0482208T3 (da) 2000-09-18
EP0482208B1 (en) 2000-07-19
AU7651191A (en) 1991-11-11
EP0482208A4 (en) 1992-10-07
TW204348B (enExample) 1993-04-21
DE69132329T2 (de) 2000-11-30
ES2149761T3 (es) 2000-11-16
KR970002876B1 (ko) 1997-03-12
JPH07107055B1 (enExample) 1995-11-15
WO1991016314A1 (en) 1991-10-31
US5202323A (en) 1993-04-13
HU208124B (en) 1993-08-30
DE69132329D1 (de) 2000-08-24
ATE194835T1 (de) 2000-08-15
HUT60253A (en) 1992-08-28
CA2053863A1 (en) 1991-10-26
GR3034331T3 (en) 2000-12-29
US5314883A (en) 1994-05-24
ZA913134B (en) 1992-04-29
JPH07107055B2 (ja) 1995-11-15
CA2053863C (en) 1996-10-29
EP0482208A1 (en) 1992-04-29
HU913497D0 (en) 1992-01-28
RU2054004C1 (ru) 1996-02-10
KR920701169A (ko) 1992-08-11
US5318968A (en) 1994-06-07
UA27031A1 (uk) 2000-02-28

Similar Documents

Publication Publication Date Title
AU634655B2 (en) Pyridazinone derivative
JPWO1991016314A1 (ja) ピリダジノン誘導体
AU2008255733B8 (en) Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor-binding activity
KR20010040912A (ko) 신규 피리다진 유도체 및 이를 유효성분으로 하는 의약
RS50544B (sr) Derivati 1-piperazin-i 1-homopiperazin-karboksilata, postupci njihovog dobijanja i primena kao inhibitora faah enzima
US8034814B2 (en) Phthalazine derivatives with angiogenesis inhibiting activity
US5476851A (en) Pyrazolo[3,4-g]quinoxaline compounds which inhibit PDGF receptor protein tyrosine kinase
SK287362B6 (sk) Derivát arylalkanoylpyridazínu, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje
RU2392269C2 (ru) Производные арилоксиалкилкарбаматов, их получение и их применение в терапии
US5929074A (en) Pyridazinone derivatives with pharmaceutical activity
US5750523A (en) Pyridazinone derivatives
AU2002330656A2 (en) Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same
WO2003082263A1 (en) Sulfamic acids as inhibitors of human cytoplasmic protein tyrosine phosphatases
EP0419286A2 (en) Pyridone nitriles useful in treating cardiovascular disease
FR2933697A1 (fr) Derives de 1-benzyl-cinnolin-4-(1h)-one substitues, leur preparation et leur application en therapeutique
CA2020027C (en) Isoquinoline- or quinoline-sulfonamide derivative and a pharmaceutical composition comprising the same
JP3666042B2 (ja) ピリダジノン誘導体
JPH0676390B2 (ja) ピリダジノン誘導体